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Change of mammographic density predicts the
risk of contralateral breast cancer - a
case-control study
Maria EC Sandberg1*, Jingmei Li1,2, Per Hall1, Mikael Hartman1,3,4, Isabel dos-Santos-Silva5, Keith Humphreys1 and
Kamila Czene1
Abstract
Introduction: Mammographic density is a strong risk factor for breast cancer, but it is unknown whether density at
first breast cancer diagnosis and changes during follow-up influences risk of non-simultaneous contralateral breast
cancer (CBC).
Methods: We collected mammograms for CBC-patients (cases, N = 211) and unilateral breast cancer patients
(controls, N = 211), individually matched on age and calendar period of first breast cancer diagnosis, type of
adjuvant therapy and length of follow-up (mean follow-up time: 8.25 years). The odds of CBC as a function of
changes of density during follow-up were investigated using conditional logistic regression, adjusting for non-
dense area at diagnosis.
Results: Patients who experienced ≥10% absolute decrease in percent density had a 55% decreased odds of CBC
(OR = 0.45 95% CI: 0.24 to 0.84) relative to patients who had little or no change in density from baseline to first
follow-up mammogram (mean = 1.6 (SD = 0.6) years after diagnosis), whereas among those who experienced an
absolute increase in percent density we could not detect any effect on the odds of CBC (OR = 0.83 95% CI: 0.24 to
2.87).
Conclusion: Decrease of mammographic density within the first two years after first diagnosis is associated with a
significantly reduced risk of CBC, this potential new risk predictor can thus contribute to decision-making in follow-
up strategies and treatment.
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Introduction
Mammographic density is one of the strongest risk fac-
tors for breast cancer; a meta-analysis of 14,000 cases
and 226,000 non-cases showed that the women with
>75% mammographic density have almost five times the
risk of breast cancer compared to women in the lowest
density group (<5%) [1]. Mammographic density has
also been shown to be important for breast cancer
recurrence [2] and survival [3]. Several hormonal factors
affect mammographic density and changes of density
have been shown to be associated with pharmacological
therapies, such as hormone replacement therapy [4] and
tamoxifen [5].
Despite the well-known and strong association between
mammographic density and unilateral breast cancer, the
effect of mammographic density on the risk of a second
primary breast cancer in the opposite breast, contralat-
eral breast cancer (CBC), has to our knowledge not been
investigated before. Breast cancer patients have approxi-
mately double the risk of CBC, compared to healthy
women’s risk of breast cancer [6] and this increased risk
does not seem to decline with time after first diagnosis
[7-9]. This translates into 10 to 15% of all breast cancer
patients being diagnosed with CBC within 20 years of
initial diagnosis [10,11]. When investigating hormonal
risk factors for unilateral breast cancer no association
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with risk of CBC has been identified [12-14]. Trends of
breast cancer incidence and breast cancer mortality indi-
cate that CBC will be a greater clinical challenge in the
future, since the population at risk of CBC is increasing
[15]. Since CBC also has a far less well characterized risk
profile [8] and considerably worse prognosis than unilat-
eral breast cancer, new tools for prediction of CBC would
be of great clinical importance [16].
The question of whether decreasing mammographic
density is associated with a decreased future risk of
breast cancer, or not, has been investigated in several
observational studies. Two showed an association
[17,18] and one did not [19]. The question was also
examined in a randomized trial of tamoxifen among
healthy women at high risk of breast cancer, for which
the estimated association was more pronounced among
the tamoxifen treated, although the association (albeit
non-statistically significant) was also seen among the
women who received placebo [20]. If this association
were also present among breast cancer patients, for the
risk of CBC, this would have important clinical implica-
tions for follow-up care. The aim of this matched nested
case-control study was, therefore, to assess whether
change of mammographic density after the first breast
cancer diagnosis predicts a change in risk of CBC.
Methods
Study population
The study was nested within the catchment population of
the Stockholm Breast Cancer Register, a population-
based register of all breast cancer patients diagnosed
since 1976 in the Stockholm-Gotland health-care region
(N >30,000). Women with invasive CBC diagnosed more
than one year after the first invasive cancer and with an
available mammogram close to the first diagnosis (N =
458) were identified as potential cases. Patients with inva-
sive unilateral breast cancer in the same register were
identified as potential controls. Women with a first pri-
mary cancer other than breast cancer and women with
distant metastasis at the first or second breast cancer
diagnosis were excluded in order to minimize the risk of
the CBC being a misclassified metastasis. Further, second
primary breast cancers can obviously also occur in the
same breast as the first cancer; ipsilateral breast cancer.
We chose not to include these cancers in the present
study since also these cancers are less likely to be primary
cancers. For each case, one control was randomly
selected and matched to the corresponding case on the
calendar period of the first breast cancer diagnosis (+/-
two years), age at the first breast cancer diagnosis (+/-
two years), adjuvant therapy and follow-up time, so that
the control had survived without distant metastasis or
CBC at least as long as the time between the first and
second cancer for the corresponding case, a strategy
known as density sampling [21]. From the Stockholm
Breast Cancer Register we retrieved information on
menopausal status at the time of the (first) breast cancer
diagnosis, estrogen receptor (ER) status and tumor-node-
metastasis (TNM)-stage of the (first) cancer, in addition
to the matching variables. From the medical records of
the cases and controls we retrieved information on hor-
mone replacement therapy at the time of the (first) breast
cancer diagnosis as well as additional information on
menopausal status and ER-status.
We collected baseline and follow-up mammograms for
the cases and controls. The baseline mammogram was
defined as a mammogram from the contralateral breast,
that is, the breast not affected by cancer, taken at any
time during the year prior to diagnosis, or within two
weeks after diagnosis, of the first cancer. Follow-up
mammograms were defined as mammograms from the
unaffected, contralateral breast taken at least one year,
but no more than five years, after diagnosis of the first
cancer. We used the first available mammogram in the
defined time period. We defined sets of two individuals
comprising one CBC case and one matched control
(unilateral breast cancer patient) and a total of four
mammograms (one baseline and one follow-up mam-
mogram for each patient) of the same view. The media-
lateral-oblique (MLO) view of mammograms have been
the preferred view in the Swedish screening program
[22] and were, therefore, used for our primary selection.
Sets of cranial-caudal (CC)-mammograms made up 14%
of the final sample.
For 99 of the 458 eligible CBC-cases we could not
locate any follow-up mammogram and for 88 of the
CBC-cases either the baseline or the follow-up mammo-
gram could not be used (for example, due to low quality
of the mammogram), while for 271 patients (59%) both
the baseline and at least one follow-up mammogram of
the unaffected breast from the same view was assessable
and could be used. Among these patients we could trace
the baseline and follow-up mammograms from the cor-
rect side and view for the corresponding control in 211
cases. These 211 case-control sets were thus included in
the analysis sample. The CBC patients excluded due to
lack of eligible mammograms did not differ from those
included in the analysis in relation to age or calendar
period of first diagnosis.
For comparison with the risk of CBC as a function of
baseline mammographic density (that is, density at the
time of first breast cancer diagnosis), we also examined
the risk of unilateral breast cancer in relation to mammo-
graphic density. To achieve this, for each unilateral breast
cancer case, we also measured the mammographic den-
sity of a healthy woman. The healthy controls (N = 142)
were randomly selected from a breast cancer case-control
study, extensively described elsewhere [23], for which all
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available mammograms had been previously collected.
The mammograms of the healthy controls were matched
to the unilateral breast cancer patients by calendar period
and age of the corresponding unilateral breast cancer
patient at her first diagnosis.
The mammograms were digitized using an Array
2905HD Laser Film Digitizer (Array Corporation,
Tokyo, Japan), which covers a range of 0 to 4.7 optical
density. The density resolution was set at 12-bit spatial
resolution. Mammographic density was measured using
our automated thresholding method [24], which incor-
porates the knowledge of a trained observer by using
measurements obtained by an established user-assisted
threshold method - Cumulus [25] - as training data.
The externally validated results showed a high corre-
spondence between our automated method and the
established user-assisted thresholding method Cumulus
(rpercent mammographic density) = 0.88 (95% CI: 0.87 to 0.89).
Statistical analysis
We estimated the percent mammographic density as well
as the absolute size of the dense area and of the total area
of the breast. Percent density and dense area have been
used in previous studies and have both been shown to be
important predictors of breast cancer risk [26]. For
descriptive purposes we calculated the mean changes of
mammographic density (unadjusted) in different groups
of study participants.
As the first step, the risk of CBC as a function of
baseline mammographic density was analyzed using
conditional logistic regression, contrasting CBC patients
to unilateral breast cancer patients. Further, by the same
type of analysis we then contrasted the unilateral breast
cancer patients to healthy controls. Percentage density
at baseline was categorized into ≤5%, >5 to 25% (refer-
ence level), >25 to 50% and >50%; these cutoffs have
been used extensively [1]. Dense area at baseline was
categorized into: ≤20 cm2, >20 to 40 cm2 (reference
level), >40 to 60 cm2 and >60 cm2, with these categories
corresponding approximately to quartiles of the baseline
dense area distribution. Calculating also the total breast
area enabled us to adjust for non-dense area in the ana-
lyses; adjustment for this variable has recently been
shown to be preferential to adjusting for body mass
index (BMI) [27]. All analyses were thus adjusted for
age and calendar period of diagnosis, adjuvant therapy
and follow-up time (through matching) and also for
non-dense area at first diagnosis, categorized in quar-
tiles. Trend tests were carried out based on ordered
categories of percent density/dense area.
For our main analysis, conditional logistic regression
was used for analyzing risk of CBC as a function of
“change” of mammographic density from baseline to
first follow-up mammogram, categorized in three levels:
absolute decrease ≥10%, stable (-10% to +10%, reference
level) and absolute increase ≥10%, in agreement with
previous literature [20]. Further, we investigated change
of density in terms of absolute dense area, also categor-
ized in three levels: ≥10 cm2 reduction, stable (-10 cm2
to +10 cm2, reference level) and ≥10 cm2 increase in
dense area. Both analyses were adjusted through match-
ing for age and calendar period of first diagnosis, first
adjuvant therapy and follow-up time. In an additional
model, we made further adjustments for baseline non-
dense area and baseline mammographic density (percent
density when using change in percent density and dense
area when using change in dense area), both categorized
in quartiles. Patients with <10% or >90% percent mam-
mographic density at baseline (N = 66), or those with
<10 cm2 or >70 cm2 dense area (N = 84), were excluded,
since they cannot possibly undergo changes in percent
mammographic density, or dense area, of the defined
magnitude. A similar strategy has been used by others
when studying changes in mammographic density [5].
Trend test was performed using the ordinal categories of
change of percent density and area density, respectively.
Finally, as an exploratory analysis we stratified our
population on menopause status at first breast cancer to
investigate the effect of change of mammographic den-
sity on the risk of CBC in the two subgroups, adjusting
for non-dense area at baseline and percent density at
baseline. Case-control pairs discordant for menopause
status (N = 35) was not included in this analysis.
All data preparation and analyses were carried out
using SAS Statistical Package 9.2 (SAS Institute Inc.,
Cary, NC, USA). This study was approved by the Ethical
Review Board at Karolinska Institutet, Stockholm, Swe-
den. As no contact was made with the study persons
and the data were analyzed anonymously, informed con-
sent was not obtained. This exception from informed
consent was confirmed by the ethical committee.
Results
A total of 422 subjects (211 cases and 211 controls) were
included in the analysis (Table 1). The mean time from
diagnosis to follow-up mammogram was 1.6 years, 90%
of the follow-up mammograms were taken between 1
and 2.2 years after diagnosis of the first breast cancer and
there was no difference between cases and controls. The
mean breast density at baseline was 28%.
Table 2 describes the mean change of mammographic
density, measured in absolute percent density, from base-
line to follow-up mammogram. The change is similar
over the calendar period and over different categories of
total breast area. As expected, the mammographic den-
sity decreases significantly more in the women diagnosed
before menopause, compared to women diagnosed after
menopause (P-value < 0.01).
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We found no association between mammographic den-
sity at baseline and risk of CBC using either percent
mammographic density or dense area (P-value for trend:
0.40 and 0.96 for percent density and dense area, respec-
tively) (Table 3). Also, when mammographic density was
analyzed as a continuous measure no effect was found;
odds ratio (OR) for percent density: 1.00 (95% CI: 0.98 to
1.01) and for dense area: 1.00 (95% CI: 0.99 to 1.01). We
further compared the baseline density between unilateral
breast cancer patients and healthy controls. As expected,
we found a statistically significant increasing risk of
breast cancer with increasing mammographic density
Table 1 Distribution of CBC case and unilateral breast cancer controls
Cases Controls P-value*
Age at (first) diagnosis (%) ≤45 years 37 (18) 37 (18)
45 to 55 years 68 (32) 68 (32)
55 to 65 years 56 (27) 56 (27)
≥65 years 50 (24) 50 (24) -
Calendar period of (first) diagnosis (%) 1976 to 1980 31 (15) 30 (14)
1981 to 1985 40 (19) 41 (19)
1986 to 1990 45 (21) 41 (19)
1991 to 1995 51 (24) 49 (23)
1996 to 2005 44 (21) 50 (24) -
Adjuvant therapy (%)* No adjuvant therapy 39 (18) 39 (18)
Radiotherapy only 57 (27) 57 (27)
Endocrine therapy 87 (41) 87 (41)
Chemotherapy 28 (13) 28 (13) -
Mean follow-up time in years 8.25 8.25 -
Percent density at (first) diagnosis (%) ≤5% 13 (6) 11 (5)
5 to 25% 87 (41) 87 (41)
25 to 50% 97 (46) 87 (41)
≥50% 14 (7) 26 (12) 0.23
Quartiles:
Dense area at (first) diagnosis (%) ≤20 cm2 55 (26) 55 (26)
20 to 34 cm2 44 (21) 56 (27)
34 to 53 cm2 56 (27) 49 (23)
≥53 cm2 56 (27) 51 (24) 0.79
Change in percent density until first Absolute decrease (>10%) 40 (19) 56 (27)
follow-up mammogram (%) Stable density 164 (78) 143 (68)
Absolute increase (>10%) 7 (3) 12 (6) 0.07
Change in dense area until first Absolute decrease (>10 cm2) 61 (29) 75 (36)
follow-up mammogram Stable density 131 (62) 113 (54)
Absolute increase (>10 cm2) 19 (9) 23 (11) 0.21
Quartiles:
Non-dense area at (first) diagnosis (%) ≤67 cm2) 42 (20) 60 (28)
67 to 93 cm2 58 (27) 43 (20)
93 to 127 cm2 50 (24) 55 (26)
≥127 cm2 61 (29) 53 (25) 0.10
Mean time until first follow-up mammogram in years (SD) 1.56
(0.59)
1.54
(0.57)
0.56
Menopause status at diagnosis (%)** Premenopausal 89 (42) 84 (40)
Postmenopausal 119 (56) 124 (59) 0.62
Subdivided by matching variables (age at diagnosis, calendar period of diagnosis, adjuvant therapy and follow-up time), exposure variables (dense area at
diagnosis and change of dense area), potential confounding variables (non-dense area at diagnosis and time to first follow-up mammogram), and stratifying
variable (menopause status).
* P-value for Chi-square test of association when testing categorical variables and for Student’s t-tests when testing the continuous variable (mean time until first
follow-up mammogram).
*Endocrine therapy may be with or without radiotherapy, chemotherapy may be with or without radiotherapy and/or endocrine therapy.
** Six patients had uncertain menopause status (for example, hysterectomy).
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(P-values for trend: <0.01 and 0.02 for percent density
and dense area, respectively).
When analyzing change of mammographic density, we
observed a 55% lower risk of CBC for women with an
absolute decrease in mammographic density of ≥10% from
baseline to follow-up mammogram, compared to women
with stable mammographic density (OR = 0.45 (95% CI:
0.24 to 0.84)) (Table 4). We found no statistically signifi-
cant effect of increasing absolute mammographic density
compared to stable density (OR = 0.83 (95% CI: 0.24 to
2.87)). Through the matched case-control design, these
findings are independent of age and calendar period of
first diagnosis, adjuvant therapy and follow-up time. The
adjustments for non-dense area at baseline and percent
density at baseline affected the estimates only marginally,
but these variables are included since they are potential
confounders. Using absolute dense area as a measure of
mammographic density we found a similar effect of 46%
risk decrease for women with ≥10 cm2 decrease from
baseline to follow-up mammogram, compared to women
Table 2 Mean absolute change of percent density (PD) from baseline until first follow-up mammogram
N Meandecrease (%-units) 95% CI for mean decrease of PD P-value
Total 422 -3.94 -4.89, -3.00 -
CBC case/control status 0.09
Cases 211 -3.13 -4.39, -1.87
Controls 211 -4.75 -6.16, -3.34
Age at time of (first) cancer: <0.01
<45 years 74 -5.30 -8.39, -2.22
45 to 54 years 136 -5.85 -7.61, -4.10
55 to 64 years 112 -4.13 -5.60, -2.65
≥65 years 100 -0.13 -1.50, 1.25
Calendar period of (first) cancer: 0.25
1976 to 1980 62 -4.11 -7.57, -0.66
1981 to 1985 80 -3.78 -6.24, -0.32
1986 to 1990 90 -2.27 -4.09, -0.46
1991 to 1995 102 -3.91 -5.70, -2.12
1996 to 2005 88 -5.71 -7.26, -4.16
Total breast area at baseline: 0.27
Smallest quartile 103 -2.54 -4.66, -0.41
2nd quartile 105 -4.68 -6.71, -2.66
3rd quartile 110 -4.91 -6.75, -3.07
Largest quartile 104 -3.56 -5.16, -1.96
Adjuvant therapy of (first) cancer: <0.01
No adjuvant therapy 78 -1.09 -3.09, 0.92
Radiotherapy only 114 -3.22 -5.14, -1.30
Endocrine therapy (with/without radiotherapy) 174 -4.15 -5.37, -2.93
Chemotherapy (with/without other adjuvant therapy) 56 -8.74 -5.24, -12.24
Menopause status at (first) cancer:* <0.01
Premenopausal 173 -5.90 -7.70, -4.10
Postmenopausal 243 -2.56 -3.54, -1.58
Postmenopausal HRT use:* <0.01
with Current use of HRT at diagnosis 51 -6.55 -8.90, -4.19
with No current use of HRT at diagnosis 127 -1.66 -2.90, -0.43
ER-status of (first) cancer: 0.63
ER-positive 295 -4.15 -5.29, -3.01
ER-negative 53 -3.46 -5.92, -0.99
TNM-stage of (first) cancer:* 0.67
1 244 -4.06 -5.27, -2.85
2 157 -3.48 -5.10, -1.86
3 16 -5.36 -11.19, 0.47
The mean change is calculated for cases and control combined.
* Six (1%) women with unknown menopause; 65 (27%) postmenopausal women with unknown HRT. Five women with unknown TNM-stage.
TNM, tumor-node-metastasis
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with stable density (OR = 0.54; 95% CI: 0.30 to 0.99)
(Table 4). No statistically significant effect was seen for
≥10 cm2 increase of density compared to women with
stable density (OR = 0.71 (95% CI: 0.30 to 1.69)). Further,
adjustment for hormone replacement therapy affected the
estimates only marginally (OR for ≥10% decrease = 0.41
(95% CI: 0.21 to 0.78), OR for ≥10% increase = 0.87 (95%
CI: 0.25 to 3.07)) and is not included in the models.
Finally, we stratified our analysis on treatment groups;
unfortunately, only two groups had large enough power,
the patient group treated with radiotherapy only and the
patient group treated with endocrine therapy (with or
without radiotherapy). The association between decreasing
mammographic density (measured as percent density) and
risk of CBC was similar in the two groups; OR = 0.52
(95% CI: 0.18 to 1.51) for the endocrine therapy group and
OR = 0.43 (95% CI: 0.14 to 1.28) for the radiotherapy
group (data not shown in Table).
As an exploratory analysis of the effect of change of
mammographic density on CBC, we stratified our popula-
tion on menopause status at baseline mammogram.
Among the premenopausal women an absolute decrease
of mammographic density of 10% or more from baseline
to follow-up mammogram was associated with an OR of
CBC of 0.29 (95% CI: 0.09 to 0.92 (N = 164)) compared to
the reference level of stable density. The corresponding
Table 3 Odds ratio of CBC and unilateral breast cancer in relation to levels of mammographic density
Density at diagnosis CBC-patients vs.
unilateral breast cancer patients
Unilateral breast cancer patients vs. healthy women
Percent density N OR 95% CI N OR 95% CI
≤5% 24 1.28 0.52 to 3.13 19 0.58 0.20 to 1.69
>5 to 25% 174 1.00 Ref. 125 1.00 Ref.
>25 to 50% 184 1.14 0.71 to 1.82 111 2.27 1.18 to 4.37
>50% 40 0.46 0.17 to 1.21 32 2.89 1.01 to 8.21
P-value for trend* 0.40 <0.01
Area density N OR 95% CI N OR 95% CI
≤20 cm2 106 1.35 0.79 to 2.32 85 0.65 0.36 to 1.17
>20 to 40 cm2 144 1.00 Ref. 101 1.00 Ref.
>40 to 60 cm2 96 1.25 0.71 to 2.19 52 1.40 0.69 to 2.83
>60 cm2 76 1.27 0.70 to 2.29 49 1.58 0.76 to 3.26
P-value for trend* 0.96 0.02
* Trend test is based on ordered categories of percent density and dense area, respectively.
Analysis of the risk of contralateral breast cancer (CBC) is adjusted by CBC-patients being matched to unilateral breast cancer patients by age at diagnosis,
calendar period of diagnosis, follow-up time and adjuvant therapy. The analysis of risk of unilateral breast cancer is adjusted by unilateral breast cancer patients
being matched to healthy women by age at mammogram and calendar period of mammogram In addition to matching all models are also adjusted for non-
dense area at baseline mammogram. The mammographic density was measured at the time of the first breast cancer for CBC-cases and unilateral controls,
mammographic density of the healthy controls were measured in the same calendar period and at the same age as the corresponding control with unilateral
breast cancer.
Table 4 Odds ratio of CBC in relation to changes in mammographic density after first breast cancer
Post-diagnostic change of density
Percent density N OR* 95% CI OR** 95% CI
Absolute decrease ≥10% 96 0.49 0.28 to 0.85 0.45 0.24 to 0.84
Stable (<10% decrease to <10% increase) 243 1.00 Ref. 1.00 Ref.
Absolute increase ≥10% 17 0.74 0.23 to 2.40 0.83 0.24 to 2.87
P-value for trend*** 0.04 0.04
Area density N OR* 95% CI OR** 95% CI
Absolute decrease ≥10 cm2 108 0.67 0.38 to 1.16 0.54 0.30 to 0.99
Stable (<10 cm2 decrease to <10 cm2 increase) 197 1.00 Ref. 1.00 Ref.
Absolute increase ≥10 cm2 33 0.79 0.35 to 1.78 0.71 0.30 to 1.69
P-value for trend*** 0.35 0.13
* Adjusted through matching for age at diagnosis, calendar period of diagnosis, adjuvant therapy and follow-up time.
** Adjusted through matching for age at diagnosis, calendar period of diagnosis, adjuvant therapy and follow-up time, and additionally in the analyses for
percent density and non-dense area at first diagnosis.
*** Trend test is based on the ordered categories of change of percent density and dense area, respectively
Patients with <10% or >90% percent mammographic density at baseline (N = 66), or those with <10 cm2 or >70 cm2 dense area (N = 84), were excluded, since
they cannot possibly undergo changes in percent mammographic density, or dense area, of the defined magnitude A similar strategy has previously been used
by others when studying changes in mammographic density [5].
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OR for post-menopausal women was 0.49 (95% CI: 0.16 to
1.45) (N = 188). The effect of density reduction and meno-
pausal status was not statistically significant (Pinteraction =
0.47).
Finally, we stratified the mammograms by view; CC-
view (19%) and MLO-view (81%). We found very similar
estimates for the effect of decreasing mammographic
density on the risk of CBC in the two groups, although
the statistical significance was lost in the CC-view group
(OR for MLO-group: 0.45 (95% CI: 0.22 to 0.91), OR for
the CC-group: 0.42 (95% CI: 0.06 to 2.77)).
Discussion
To our knowledge, this is the first study to have investi-
gated the risk of CBC as an effect of mammographic den-
sity at the time of diagnosis of the first cancer and of its
subsequent changes. In a population-based setting we esti-
mated that an absolute decrease of mammographic density
from diagnosis to first follow-up mammogram of at least
10% confers a significant 55% decrease in risk of CBC. In
contrast, mammographic density at diagnosis does not
seem to predict risk of CBC.
Strengths of the study include its ability to investigate
both baseline density and changes after first diagnosis
and the use of both absolute (dense area) and relative
(percent density) measures of mammographic density.
The study is limited mainly by its small size, resulting
from the large proportion of cases that had to be
excluded from the analysis because the required mam-
mograms could not be traced. Exclusion of patients due
to unavailability of mammograms is a potential source
of bias if the missingness is differential; it, however,
seems unlikely that the mammograms should be missing
on the basis of mammographic density. Further, una-
voidably, access to the patient’s mammograms is a
requirement for studies of mammographic density. Reas-
suringly, the excluded patients did not differ from those
included in the analysis in relation to important factors
such as age at first diagnosis (P-value: 0.23) and calen-
dar period of first diagnosis (P-value: 0.12). There were,
however, differences with respect to adjuvant therapy
for the first cancer; the included patients had received
radiotherapy and endocrine therapy to a somewhat lar-
ger degree (radiotherapy; 29% vs. 23% for excluded
patients, endocrine therapy; 39% vs. 29% for excluded
patients). Since the study was matched for treatment,
this difference has potential implications only for the
generalizability of our results, as the patients receiving
no adjuvant therapy and the patients receiving che-
motherapy are somewhat under-represented in this
study. In general, the availability of the mammograms in
Sweden during the study period is primarily driven by
archiving policies, rather than patients not having mam-
mograms taken.
In contrast to the effect of mammographic density on
the risk of unilateral breast cancer among healthy
women, mammographic density at baseline did not
seem to influence the risk of CBC in breast cancer
patients. None of the categories of mammographic den-
sity conferred any statistically significant change in risk
from the reference group. The fact that some of the OR
estimates were decreased is most likely due to low
power in those specific categories (P-value for trend:
0.40) (Table 3). The lack of association for mammo-
graphic density at baseline is a somewhat unexpected
finding but mimics the effect of hormonal/reproductive
factors, which increases the risk of breast cancer [28,29]
but not the risk of CBC [12-14]. An alternative explana-
tion for the lack of association between mammographic
density and risk of CBC could be that there was a sys-
tematic difference in mammographic density of the uni-
lateral breast cancer patients selected as controls for the
current study, compared to unilateral breast cancer
patients in general. To investigate this concern we stu-
died the effect of mammographic density on the risk of
breast cancer in unilateral breast cancer patients com-
pared to healthy women and reassuringly found the
expected strong association between mammographic
density and the risk of breast cancer.
Our study showed that women who experienced at
least 10% decrease in mammographic density after the
first breast cancer diagnosis were at a substantially lower
risk of developing CBC than those women whose mam-
mographic density remained stable (Table 4). Two pre-
vious studies have investigated the relation between
change of mammographic density and risk of unilateral
breast cancer and showed that decreasing density was
associated with a decreasing risk of developing breast
cancer [17,18]. However, no previous study has examined
changes in density after a first diagnosis of breast cancer
in relation to risk of CBC. Not only are CBC patients a
selected subgroup of women with high susceptibility to
breast cancer, they are on average younger and have a
higher prevalence of family history of the disease.
Furthermore, a large proportion of CBC patients are trea-
ted with adjuvant therapy for their first breast cancer. In
a primary prevention study, women treated with tamoxi-
fen or placebo showed a decreased risk of breast cancer
following a decrease in mammographic density [20], the
effect was stronger among the tamoxifen-treated patients,
but present also among the non-treated, though not sta-
tistically significantly so, indicating the presence of also
other mechanisms, not mediated through tamoxifen. In
the present study, we found that the decrease in the risk
of CBC associated with a decline in mammographic den-
sity was independent of the type of adjuvant treatment
administered; when stratifying on adjuvant therapy we
did not see any indication of different effects in different
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treatment groups, but these analyses are associated with
low power.
Kerlikowske et al. [17] suggested that the effect of
change in mammographic density on the risk of unilateral
breast cancer might be more pronounced in premenopau-
sal women. We stratified our analysis on menopausal
status at first breast cancer diagnosis and although we had
low numbers for this analysis we still found a suggestion
of a stronger association between decreased density and
risk of CBC in the premenopausal women. The majority
of the premenopausal women diagnosed with breast
cancer will go through menopause relatively soon, either
naturally, due to aging, or artificially, due to adjuvant che-
motherapy [30], and the change in mammographic density
resulting from menopause is relatively large [31]. The find-
ings in the pre-menopausal group, in combination with
the findings from the analysis stratified on therapy, indi-
cate that a decrease in mammographic density, regardless
of the mechanism, might result in a subsequent decrease
in CBC-risk.
Conclusion
Our findings indicate that women who experience ≥10%
absolute decrease in mammographic density from the
first diagnosis until the first follow-up mammogram
(approximately 1.6 years later) decrease their risk of CBC
to about half. Furthermore, the association between
decreasing mammographic density and risk of CBC was
independent of therapy given for the first cancer. The
10% cutoff has been previously shown as the minimum
change that could be reproducibly detected visually [20]
and might, therefore, be clinically useful. In the present
study, 23% of the participating women experienced such
a decrease. If confirmed, change of mammographic den-
sity can be used to predict the risk of CBC, and can thus
contribute to decision-making in follow-up routines and
adjuvant treatment regimens.
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